Pharmacotherapy of severe asthma

Current Opinion in Pharmacology

Volumn 10, Issue 3, 2010, Pages 266-271

  Firszt, Rafael ^a   Kraft, Monica ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CLARITHROMYCIN; CORTICOSTEROID; CYTOKINE RECEPTOR ANTAGONIST; DACLIZUMAB; ETANERCEPT; GOLIMUMAB; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MACROLIDE; MEPOLIZUMAB; OMALIZUMAB; PITRAKINRA; PLACEBO; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; ZILEUTON; ANTIASTHMATIC AGENT; GLUCOCORTICOID; IMMUNOLOGIC FACTOR;

ADD ON THERAPY; ALLERGIC ASTHMA; ANAPHYLAXIS; ASTHMA; BRONCHIAL THERMOPLASTY; BRONCHOSCOPY; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; HUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOFREQUENCY; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; SEVERITY OF ILLNESS INDEX;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; PHENOTYPE; SEVERITY OF ILLNESS INDEX;

EID: 77954660795     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2010.04.010     Document Type: Review

References (50)

1. Moore W.C., Bleecker E.R., Curran-Everett D., Erzurum S.C., Ameredes B.T., Bacharier L., Calhoun W.J., Castro M., Chung K.F., Clark M.P., et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007, 119:405-413.
2. Proceedings of the ATS workshop on Refractory Asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000, 162:2341-2351. American Thoracic Society.
3. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype pf chronic severe asthma. Eur Respir J 2003, 22:470-477. The ENFUMOSA Study Group.
4. The American Lung Association Asthma Clinical Research Centers Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med 2009, 360:1487-1499.
5. Littner M.R., Leung F.W., Ballard E.D., Huang B., Samra N.K. Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. Chest 2005, 128:1128-1135.
6. Kiljander T.O., Harding S.M., Field S.K., Stein M.R., Nelson H.S., Ekelund J., Illueca M., Beckman O., Sostek M.B. Effects of esomeprazole 40mg twice daily on asthma: a randomized placebo controlled trial. Am J Respir Crit Care Med 2006, 173:1091-1097.
7. Peters-Golden M., Swern A., Bird S.S., Hustad C.M., Grant E., Edelman J.M. Influence of body mass index on the response to asthma controller agents. Eur Respir J 2006, 27:495-503.
8. Sutherland E.R., Goleva E., Strand M., Beuther D.A., Leung D.Y. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med 2008, 178:682-687.
9. National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma [Internet]. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007 [accessed December 2009]. Available from http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.
10. Gibson P., Powell H., Ducharme F.J. Long acting ß2-agonists as an inhaled corticosteroid sparing agent for chronic asthma in adults and children. Cochrane Database Syst Rev 2005, 4:CD005076.
11. Wechsler M.E., Lehman E., Lazarus S.C., Lemanske R.F., Boushey H.A., Deykin A., Fahy J.V., Sorkness C.A., Chinchilli V.M., Craig T.J., et al. Beta-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006, 173:519-526.
12. 2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 2009, 374:1754-1764.
13. 2-Receptor polymorphisms in patients receiving salmeterol with or without ßuticasone propionate. Am J Respir Crit Care Med 2010, 181:676-687.
14. Ayres J.G., Jyothish D., Ninan T. Brittle asthma. Paediatr Respir Rev 2004, 5:40-44.
15. Johnston S.L., Martin R.J. Chlamydophila pneumoniae and Mycoplasma pneumoniae: a role in asthma pathogenesis?. Am J Respir Crit Care Med 2005, 172:1078-1089.
16. Hahn D.L., Anttila T., Saikku P. Association of Chlamydia pneumoniae IgA antibodies with recently symptomatic asthma. Epidemiol Infect 1996, 117:513-517.
17. Martin R.J., Kraft M., Chu H.W., Berns E.A., Cassell G.H. A link between chronic asthma and chronic infection. J Allergy Clin Immunol 2001, 107:595-601.
18. Sakito O., Kadota J., Kohno S., Abe K., Shirai R., Hara K. Interleukin 1ß, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996, 63:42-48.
19. Oda H., Kadota J., Kohno S., Hara K. Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis. Chest 1994, 106:1116-1123.
20. Li Y., Azuma A., Takahashi S., Usuki J., Matsuda K., Aoyama A., Kudoh S. Fourteen-membered ring macrolides inhibit vascular cell adhesion molecule 1 messenger RNA induction and leukocyte migration: role in preventing lung injury and fibrosis in bleomycin-challenged mice. Chest 2002, 122:2137-2145.
21. Yamaryo T., Oishi K., Yoshimine H., Tsuchihashi Y., Matsushima K., Nagatake T. Fourteen-member macrolides promote the phosphatidylserine receptor-dependent phagocytosis of apoptotic neutrophils by alveolar macrophages. Antimicrob Agents Chemother 2003, 47:48-53.
22. Kraft M., Cassell G.H., Pak J., Martin R.J. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest 2002, 121:1782-1788.
23. Black P.N., Blasi F., Jenkins C.R., Scicchitano R., Mills G.D., Rubinfeld A.R., Ruffin R.E., Mullins P.R., Dangain J., Cooper B.C., David D.B., et al. Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 2001, 164:536-541.
24. Garey K.W., Rubinstein I., Gotfried M.H., Khan I.J., Varma S., Danziger L.H. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest 2000, 118:1826-1827.
25. Richeldi L., Ferrara G., Fabbri L.M., Lasserson T.J., Gibson P.G. Macrolides for chronic asthma. Cochrane Database Syst Rev 2005, 3:CD002997.
26. Simpson J.L., Powell H., Boyle M., Scott R.J., Gibson P.G. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008, 177:148-155.
27. Milgrom H., Fick R.B., Su J.Q., Reimann J.D., Bush R.K., Watrous M.L., Metzger W.J. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMab-E25 Study Group. N Engl J Med 1999, 341:1966-1973.
28. Busse W., Corren J., Lanier B.Q., McAlary M., Fowler-Taylor A., Cioppa G.D., van As A., Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001, 108:184-190.
29. Bousquet J., Wenzel S., Holgate S., Lumry W., Freeman P., Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004, 125:1378-1386.
30. Holgate S.T., Chuchalin A.G., Hébert J., Lötvall J., Persson G.B., Chung K.F., Bousquet J., Kerstjens H.A., Fox H., Thirlwell J., et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004, 34:632-638.
31. Walker S., Monteil M., Phelan K., Lasserson T.J., Walters E.H. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006, 2:CD003559.
32. Cox L., Platts-Mills T.A., Finegold I., Schwartz L.B., Simons F.E., Wallace D.V. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007, 120:1373-1377.
33. Corren J., Casale T.B., Lanier B., Buhl R., Holgate S., Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy 2009, 39:788-797.
34. Howarth P.H., Babu K.S., Arshad H.S., Lau L., Buckley M., McConnell W., Beckett P., Al Ali M., Chauhan A., Wilson S.J., et al. Tumour Necrosis Factor (TNF-α) as a novel therapeutic target in symptomatic corticosteroid-dependent asthma. Thorax 2005, 60:1012-1018.
35. Cazzola M., Polosa R. Anti-TNF-alpha and Th1 cytokine-directed therapies for the treatment of asthma. Curr Opin Allergy Clin Immunol 2006, 6:43-50.
36. Howarth P.H., Babu K.S., Arshad H.S., Lau L., Buckley M., McConnell W., Beckett P., Al Ali M., Chauhan A., Wilson S.J., et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005, 60:1012-1018.
37. Berry M.A., Hargadon B., Shelley M., Parker D., Shaw D.E., Green R.H., Bradding P., Brightling C.E., Wardlaw A.J., Pavord I.D. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006, 354:697-708.
38. Morjaria J.B., Chauhan A.J., Babu K.S., Polosa R., Davies D.E., Holgate S.T. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 2008, 63:584-591.
39. Wenzel S.E., Barnes P.J., Bleecker E.R., Bousquet J., Busse W., Dahlén S.E., Holgate S.T., Meyers D.A., Rabe K.F., Antczak A., et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009, 179:549-558.
40. Beuther D.A., Weiss S.T., Sutherland E.R. Obesity and asthma. Am J Respir Crit Care Med 2006, 174:112-119.
41. Busse W.W., Israel E., Nelson H.S., Baker J.W., Charous B.L., Young D.Y., Vexler V., Shames R.S. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med 2008, 178:1002-1008. Daclizumab Asthma Study Group.
42. Leckie M.J., ten Brinke A., Khan J., Diamant Z., O'Connor B.J., Walls C.M., Mathur A.K., Cowley H.C., Chung K.F., Djukanovic R., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356:2144-2148.
43. Kips J.C., O'Connor B.J., Langley S.J., Woodcock A., Kerstjens H.A., Postma D.S., Danzig M., Cuss F., Pauwels R.A. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003, 167:1655-1659.
44. Flood-Page P., Swenson C., Faiferman I., Matthews J., Williams M., Brannick L., Robinson D., Wenzel S., Busse W., Hansel T.T., et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007, 176:1062-1071.
45. Haldar P., Brightling C.E., Hargadon B., Gupta S., Monteiro W., Sousa A., Marshall R.P., Bradding P., Green R.H., Wardlaw A.J., Pavord I.D. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009, 360:973-984.
46. Nair P., Pizzichini M.M., Kjarsgaard M., Inman M.D., Efthimiadis A., Pizzichini E., Hargreave F.E., O'Byrne P.M. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009, 360:985-993.
47. Wenzel S., Wilbraham D., Fuller R., Burmeister Getz E., Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007, 370:1422-1431.
48. Cox G., Thomson N.C., Rubin A.S., Niven R.M., Corris P.A., Siersted H.C., Olivenstein R., Pavord I.D., McCormack D., Chaudhuri R., et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med 2007, 356:1327-1337.
49. Castro M., Rubin A.S., Laviolette M., Fiterman J., De Andrade Lima M., Shah P.L., Fiss E., Olivenstein R., Thomson N.C., Niven R.M., et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010, 181:116-124.
50. Pavord I.D., Cox G., Thomson N.C., Rubin A.S., Corris P.A., Niven R.M., Chung K.F., Laviolette M. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med 2007, 176:1185-1191. RISA Trial Study Group.